Evidence map›Paper›PMID 42085696›Full record

ArticleJournal of medicinal chemistry2026

Development of High-Affinity CHD1 Chromodomain Inhibitors.

Holger Greschik, Florian Friedrich, Ludwig Seifert, Farnoush Mousavizadeh, Francesco Fiorentino, Johannes Walz, Lin Zhang, Jianyu Li, Emanuele Fabbrizi, Stefano Tomassi and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Holger GreschikDepartment of Urology and Center for Clinical Research, University Freiburg Medical Center, Breisacher Str. 66, 79106 Freiburg, Germany.
Florian FriedrichInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.ORCID 0000-0001-5420-6184
Ludwig SeifertInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.
Farnoush MousavizadehInstitute of Organic Chemistry, University of Freiburg, Albertstr. 21, 70104 Freiburg, Germany.
Francesco FiorentinoDepartment of Biochemical Sciences, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-3550-1860
Johannes WalzInstitute of Organic Chemistry, University of Freiburg, Albertstr. 21, 70104 Freiburg, Germany.
Lin ZhangInstitute of Biochemistry, University of Freiburg, 79104 Freiburg, Germany.
Jianyu LiInstitute of Pharmaceutical Sciences, University of Freiburg, Hermann-Herder-Str. 9, 79104 Freiburg, Germany.
Emanuele FabbriziDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Stefano TomassiDepartment of Life Science, Health and Health Professions, LINK Campus University, Via del Casale di San Pio V, 44, CAP 00165 Rome, Italy.ORCID 0000-0003-3152-4467
Farhad PanahiInstitute of Organic Chemistry, University of Freiburg, Albertstr. 21, 70104 Freiburg, Germany.ORCID 0000-0003-0420-4409
Niklas PapenkordtInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.ORCID 0000-0003-3420-0695
Silas L WurnigInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.
Johannes OsterrothInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.
Anna M StrasserInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.ORCID 0009-0003-7659-7077
Jan RuprechtInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.ORCID 0009-0003-2949-0250
Aurélien F A MoumbockInstitute of Pharmaceutical Sciences, University of Freiburg, Hermann-Herder-Str. 9, 79104 Freiburg, Germany.ORCID 0000-0002-6034-2016
Martin HügleInstitute of Pharmaceutical Sciences, University of Freiburg, Hermann-Herder-Str. 9, 79104 Freiburg, Germany.
Manuela SumDepartment of Urology and Center for Clinical Research, University Freiburg Medical Center, Breisacher Str. 66, 79106 Freiburg, Germany.
Ling PengDepartment of Urology and Center for Clinical Research, University Freiburg Medical Center, Breisacher Str. 66, 79106 Freiburg, Germany.
Sheng WangDepartment of Urology and Center for Clinical Research, University Freiburg Medical Center, Breisacher Str. 66, 79106 Freiburg, Germany.ORCID 0000-0002-2813-9878
Adina A BaniahmadInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.
Laura Pulido-CortésGerman Cancer Consortium (DKTK), Partner Site Freiburg, University Medical Center Freiburg, Breisacher Str. 66, 79106 Freiburg, Germany.ORCID 0009-0008-5829-2161
H Th Marc TimmersGerman Cancer Consortium (DKTK), Partner Site Freiburg, University Medical Center Freiburg, Breisacher Str. 66, 79106 Freiburg, Germany.ORCID 0000-0001-7062-1417
Ralf FlaigDiamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, Oxfordshire OX11 0DE, United Kingdom.
Eric MetzgerDepartment of Urology and Center for Clinical Research, University Freiburg Medical Center, Breisacher Str. 66, 79106 Freiburg, Germany.
Bernhard BreitInstitute of Organic Chemistry, University of Freiburg, Albertstr. 21, 70104 Freiburg, Germany.ORCID 0000-0002-2514-3898
Oliver EinsleInstitute of Biochemistry, University of Freiburg, 79104 Freiburg, Germany.
Stefan GüntherInstitute of Pharmaceutical Sciences, University of Freiburg, Hermann-Herder-Str. 9, 79104 Freiburg, Germany.ORCID 0000-0003-3744-189X
Dante RotiliDepartment of Science, Roma Tre University of Rome, Viale Guglielmo Marconi 446, 00146 Rome, Italy.ORCID 0000-0002-8428-8763
Antonello MaiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-9176-2382
Roland SchüleDepartment of Urology and Center for Clinical Research, University Freiburg Medical Center, Breisacher Str. 66, 79106 Freiburg, Germany.
Manfred JungInstitute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany.ORCID 0000-0002-6361-7716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chromatin remodeler CHD1, a regulator of gene activity and potential drug target in prostate cancer (PCa), contains a tandem chromodomain (tCD) binding histone H3 trimethylated at lysine 4 (H3K4me3). We developed the first submicromolar inhibitors (

Indexed as

DNA-Binding ProteinsDNA HelicasesQuinolinesBinding SitesCell Line, TumorCrystallography, X-RayHistonesHumansModels, MolecularStructure-Activity RelationshipCHD1 protein, humanDNA-Binding ProteinsDNA HelicasesHistonesQuinolines

Identifiers

PMID42085696
PMCPMC13224165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.